Glenmark Pharmaceuticals, a leading Indian pharmaceutical company, has expressed confidence that its cancer drug, Trastuzumab Rezetecan (SHR-A1811), will enter licensed markets by FY28, driving an improvement in both gross and EBITDA margins. The company has guided for an EBITDA margin of 23% for the ongoing fiscal year and expects its higher-margin oncology assets to lift profitability. Trastuzumab Rezetecan, a HER2-targeted ADC, was in-licensed from China’s Hengrui Pharma in September 2025 for an upfront payment of $18 million and milestone payments of up to $1.093 billion.
Glenmark’s Chairman and MD, Glenn Saldanha, stated that the company’s oncology assets, including Trastuzumab Rezetecan and aumolertinib, will bring meaningful gains from FY28, driving long-term growth for the company. The company has also obtained exclusive rights for select markets, including India, and is exploring the treatment of HER2-positive cancers, such as non-small cell lung cancer (NSCLC) and breast cancer.
In addition to oncology, Glenmark’s leading respiratory asset, Ryaltris, is on track to become a $100 million brand on a moving annual basis. The company is also progressing well with its $1.9 billion out-licensing deal with AbbVie for the cancer asset ISB 2001, with Phase II trials expected to begin by the end of the current calendar year.
Glenmark has a net cash position of around Rs 600 crore and has reiterated its target to reduce gross debt to zero by March 2026. The company’s innovation spin-off, IGI, has an annual cash burn of $70 million. Commenting on the Union Budget 2026-27 announcement of Biopharma SHAKTI, a scheme to boost capacity creation for biologics and biosimilars, Saldanha said it is a positive development for the industry, although Glenmark does not currently have in-house manufacturing for biologics.
Overall, Glenmark is poised for growth driven by its oncology assets, and the company is confident that its strategic decisions will yield meaningful gains from FY28. With a strong focus on innovation and a robust pipeline of products, Glenmark is well-positioned to drive long-term growth and expansion in the pharmaceutical industry. The company’s commitment to reducing debt and increasing profitability is also expected to yield positive results, making it an attractive player in the Indian pharmaceutical sector.